Satralizumab Approval Status for MOGAD
Satralizumab (Enspryng) is currently NOT approved for MOGAD and there is no publicly announced expected approval date. The drug is only FDA-approved for neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adult patients 1.
Current Clinical Trial Landscape
While satralizumab remains investigational for MOGAD, several key points emerge from the available evidence:
Active Investigation
- Satralizumab is among the targeted immunotherapies under active clinical investigation for MOGAD, alongside tocilizumab, azathioprine, and rozanolixizumab 2
- The drug is being studied in ongoing phase 2/3 trials, though specific MOGAD trial names and completion dates are not detailed in the provided evidence 2
Mechanism and Rationale
The drug works as an IL-6 receptor antagonist, blocking interleukin-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors 1. This mechanism is theoretically relevant to MOGAD pathophysiology, though the precise therapeutic mechanism in demyelinating diseases remains incompletely understood 1.
Real-World Evidence in MOGAD
Recent observational data provides some insight into IL-6 receptor blockers (including satralizumab) for MOGAD:
- A 2026 multicenter retrospective study included 116 MOGAD patients treated with IL-6 receptor blockers, of which only 12 (10%) received satralizumab (the remaining 90% received tocilizumab) 3
- The study showed reduced annualized relapse rates with IL-6 receptor blockade, though the small satralizumab subset limits specific conclusions about this agent 3
Timeline Considerations
The evidence suggests regulatory approval may occur "in the next five years" if ongoing trials demonstrate efficacy and biomarker-driven strategies are refined 2. However, this represents expert speculation rather than confirmed regulatory timelines.
Critical Caveats
- No approved therapies currently exist for MOGAD, making treatment empirical with significant variability in clinical response 2, 4, 5
- The drug label explicitly states satralizumab's mechanism in NMOSD is "unknown but presumed" to involve IL-6 inhibition, and safety/efficacy in pediatric populations remain unestablished 1
- Severe infections occurred in 9% of patients in observational MOGAD studies using IL-6 receptor blockers 3
For current clinical practice, satralizumab remains off-label for MOGAD and should only be considered in the context of clinical trials or when other evidence-based approaches have failed, given the lack of regulatory approval and limited MOGAD-specific safety data.